RxDoctor Payments Data

Jonathan Branch, MD

Cardiovascular Disease · Reidsville, NCNPI 1609035757

Payments from drug & device makers

$480in general payments, 2019–2025

Across 20 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$153
  • United Therapeutics Corporation$100
  • Cvrx, Inc.$40
  • Novartis$37
  • Abbott$31
  • Irhythm Technologies, Inc.$29
  • plus $89 from 5 others

What the payments were for

  • Speaking & faculty fees$10021%
  • Food & beverage$38079%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$480 in reported general payments places this provider in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$73,243
Medicare patients
733
Services billed
1,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,070$836,897
XareltoRivaroxaban268$196,794
EntrestoSacubitril/Valsartan200$192,665
Repatha SureclickEvolocumab153$114,502
FarxigaDapagliflozin Propanediol82$67,069
JardianceEmpagliflozin29$30,096
BrilintaTicagrelor28$18,416
VascepaIcosapent Ethyl26$8,856
Metoprolol Succinate683$7,977
Torsemide233$7,732
Rosuvastatin Calcium552$6,021
Atorvastatin Calcium740$5,824
Ranolazine ErRanolazine75$5,642
Isosorbide Mononitrate ErIsosorbide Mononitrate464$5,533
Diltiazem 24hr Er (Cd)Diltiazem Hcl199$4,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$836,8971,070 claims
Johnson & JohnsonXarelto$14$196,794268 claims
NovartisEntresto$37$192,665200 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Reidsville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →